In recent news regarding CareDx (CDNA, Financial), Craig-Hallum analyst Connor Chamberlain has maintained a "Buy" rating on the stock. However, the analyst has adjusted the price target downward, reflecting new market conditions. The revised price target is now set at USD 26.00, down from the previous target of USD 40.00.
This adjustment indicates a 35% decrease in the price target for CareDx (CDNA, Financial). Despite the lowered price target, the maintained "Buy" rating suggests continued confidence in the stock, albeit with adjusted expectations.
Investors in CareDx (CDNA, Financial) and market watchers will likely pay close attention to further developments and analysis from Craig-Hallum and other analysts as the stock navigates the evolving market landscape.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for CareDx Inc (CDNA, Financial) is $29.57 with a high estimate of $40.00 and a low estimate of $19.00. The average target implies an upside of 143.92% from the current price of $12.12. More detailed estimate data can be found on the CareDx Inc (CDNA) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, CareDx Inc's (CDNA, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CareDx Inc (CDNA, Financial) in one year is $18.84, suggesting a upside of 55.4% from the current price of $12.1235. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CareDx Inc (CDNA) Summary page.
